151 related articles for article (PubMed ID: 21122388)
1. [Clinical observation of transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma].
Xu LT; Chen Z; Lin JH; Zhou ZH; Chen H; Meng ZQ; Liu LM
Zhonghua Zhong Liu Za Zhi; 2010 Sep; 32(9):703-5. PubMed ID: 21122388
[TBL] [Abstract][Full Text] [Related]
2. [Clinical analysis of the treatment:transcatheter arterial chemoembolization combined with sorafenib in advanced hepatocellular carcinoma].
Li Y; Huang JW; Lu LG; Shao PJ; Hu BS; Huang GM; Wei ZG; Zhang L
Zhonghua Yi Xue Za Zhi; 2010 Aug; 90(31):2187-92. PubMed ID: 21029658
[TBL] [Abstract][Full Text] [Related]
3. [Clinical observation of the treatment with combination of transcatheter arterial chemoembolization and sorafenib for hepatocellular carcinoma with lung metastasis].
Duan F; Wang MQ; Liu FY; Wang ZJ; Song P
Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):716-8. PubMed ID: 20021873
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma.
Qu XD; Chen CS; Wang JH; Yan ZP; Chen JM; Gong GQ; Liu QX; Luo JJ; Liu LX; Liu R; Qian S
BMC Cancer; 2012 Jun; 12():263. PubMed ID: 22721173
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma.
Park JW; Koh YH; Kim HB; Kim HY; An S; Choi JI; Woo SM; Nam BH
J Hepatol; 2012 Jun; 56(6):1336-42. PubMed ID: 22314421
[TBL] [Abstract][Full Text] [Related]
6. Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study.
Dufour JF; Hoppe H; Heim MH; Helbling B; Maurhofer O; Szucs-Farkas Z; Kickuth R; Borner M; Candinas D; Saar B
Oncologist; 2010; 15(11):1198-204. PubMed ID: 21036880
[TBL] [Abstract][Full Text] [Related]
7. The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma.
Cabrera R; Pannu DS; Caridi J; Firpi RJ; Soldevila-Pico C; Morelli G; Clark V; Suman A; George TJ; Nelson DR
Aliment Pharmacol Ther; 2011 Jul; 34(2):205-13. PubMed ID: 21605146
[TBL] [Abstract][Full Text] [Related]
8. Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794].
Hoffmann K; Glimm H; Radeleff B; Richter G; Heining C; Schenkel I; Zahlten-Hinguranage A; Schirrmacher P; Schmidt J; Büchler MW; Jaeger D; von Kalle C; Schemmer P
BMC Cancer; 2008 Nov; 8():349. PubMed ID: 19036146
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and the strategy to treat the side effects of sorafenib administration after transarterial chemoembolization in advanced hepatocellular carcinoma patients.
Zhang K; Sun X; Xie F; Jian W; Li C
J Cancer Res Ther; 2018 Jan; 14(1):196-200. PubMed ID: 29516985
[TBL] [Abstract][Full Text] [Related]
10. [Clinical observation of sorafenib monotherapy in Chinese patients with advanced hepatocellular carcinoma].
Xu L; Li P; Lin XJ; Yuan YF; Zhang YQ; Chen MS
Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):58-61. PubMed ID: 19538872
[TBL] [Abstract][Full Text] [Related]
11. Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib.
Pinter M; Hucke F; Graziadei I; Vogel W; Maieron A; Königsberg R; Stauber R; Grünberger B; Müller C; Kölblinger C; Peck-Radosavljevic M; Sieghart W
Radiology; 2012 May; 263(2):590-9. PubMed ID: 22438359
[TBL] [Abstract][Full Text] [Related]
12. Early prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization plus sorafenib.
Meng XC; Chen BH; Huang JJ; Huang WS; Cai MY; Zhou JW; Guo YJ; Zhu KS
World J Gastroenterol; 2018 Jan; 24(4):484-493. PubMed ID: 29398869
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation.
TAN WF; Qiu ZQ; YU Y; RAN RZ; YI B; LAU WY; LIU C; QIU YH; FENG FL; WANG JH; YAN PN; ZHANG BH; WU MC; LUO XJ; JIANG XQ
Acta Pharmacol Sin; 2010 Dec; 31(12):1643-8. PubMed ID: 21102481
[TBL] [Abstract][Full Text] [Related]
14. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial.
Chao Y; Chung YH; Han G; Yoon JH; Yang J; Wang J; Shao GL; Kim BI; Lee TY
Int J Cancer; 2015 Mar; 136(6):1458-67. PubMed ID: 25099027
[TBL] [Abstract][Full Text] [Related]
15. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
Li L; Zhao W; Wang M; Hu J; Wang E; Zhao Y; Liu L
BMC Gastroenterol; 2018 Sep; 18(1):138. PubMed ID: 30180810
[TBL] [Abstract][Full Text] [Related]
16. [Therapeutic efficacy and prognostic factors of sorafenib treatment in patients with unresectable primary hepatocellular carcinoma].
Zhang L; Ren ZG; Gan YH; Wang YH; Zhang BH; Chen Y; Xie XY; Ge NL; Ye SL
Zhonghua Zhong Liu Za Zhi; 2010 Aug; 32(8):630-3. PubMed ID: 21122420
[TBL] [Abstract][Full Text] [Related]
17. Conventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma: a pilot study.
Sieghart W; Pinter M; Reisegger M; Müller C; Ba-Ssalamah A; Lammer J; Peck-Radosavljevic M
Eur Radiol; 2012 Jun; 22(6):1214-23. PubMed ID: 22215073
[TBL] [Abstract][Full Text] [Related]
18. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumour thrombus.
Pan T; Li XS; Xie QK; Wang JP; Li W; Wu PH; Zhao M
Clin Radiol; 2014 Dec; 69(12):e553-61. PubMed ID: 25304928
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma.
Pawlik TM; Reyes DK; Cosgrove D; Kamel IR; Bhagat N; Geschwind JF
J Clin Oncol; 2011 Oct; 29(30):3960-7. PubMed ID: 21911714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]